Maze Therapeutics, Inc.
MAZE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,187 | $538 | $482 | $699 |
| - Cash | $317 | $265 | $294 | $197 |
| + Debt | $24 | $25 | $26 | $27 |
| Enterprise Value | $894 | $299 | $214 | $528 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$30 | -$33 | -$35 | -$29 |
| % Margin | – | – | – | – |
| Net Income | -$30 | -$34 | -$33 | -$30 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.66 | -0.77 | -0.749 | -0.112 |
| % Growth | 14.3% | -2.9% | -568.4% | – |
| Operating Cash Flow | -$25 | -$30 | -$30 | -$22 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$25 | -$30 | -$30 | -$23 |